コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tum PCR-positive without confirmed/suspected bacterial pneumonia).
2 se (COPD)) as well as acute infections (e.g. bacterial pneumonias).
3 n to facilitate the clearance and control of bacterial pneumonia.
4 andidiasis, tuberculosis, herpes zoster, and bacterial pneumonia.
5 ption for monotherapy for community-acquired bacterial pneumonia.
6 acterial pneumonia and ventilator-associated bacterial pneumonia.
7 effective as the parent stem cells in severe bacterial pneumonia.
8 cterial clearance, and survival after severe bacterial pneumonia.
9 nfluenza-induced susceptibility to secondary bacterial pneumonia.
10 ve edema formation and facilitated secondary bacterial pneumonia.
11 gently needed to protect the vulnerable from bacterial pneumonia.
12 tilation for severe COVID-19 disease died of bacterial pneumonia.
13 , protein, and bacteria in mice injured with bacterial pneumonia.
14 ing unlikely and 129 (3.4%) as having likely bacterial pneumonia.
15 ed by a lethal dose of LPS or by Pseudomonas bacterial pneumonia.
16 ty and increases susceptibility to secondary bacterial pneumonia.
17 ngal colonization favored the development of bacterial pneumonia.
18 children, PIV pneumonia was less severe than bacterial pneumonia.
19 n and antimicrobial resistance in fungal and bacterial pneumonia.
20 ther bronchoalveolar lavage amylase predicts bacterial pneumonia.
21 eristic of perhaps all infections, including bacterial pneumonia.
22 risk factors for aspiration and may predict bacterial pneumonia.
23 , consequently, the prevalence of subsequent bacterial pneumonia.
24 pathogens known to cause community-acquired bacterial pneumonia.
25 nces antimicrobial activity in gram-negative bacterial pneumonia.
26 ans organizing pneumonia after 2 episodes of bacterial pneumonia.
27 ity in the lung in response to Gram-negative bacterial pneumonia.
28 structure infections and community-acquired bacterial pneumonia.
29 es, during acute extracellular Gram-negative bacterial pneumonia.
30 n structure infection and community-acquired bacterial pneumonia.
31 activity is crucial for host defense against bacterial pneumonia.
32 penic recipient mice in both peritonitis and bacterial pneumonia.
33 ctions and enhanced development of secondary bacterial pneumonia.
34 h leptin contributes to host defense against bacterial pneumonia.
35 immunostimulatory strategy in patients with bacterial pneumonia.
36 uired for optimal host defense against acute bacterial pneumonia.
37 rn may contribute to disease pathogenesis of bacterial pneumonia.
38 ity and increase susceptibility to secondary bacterial pneumonia.
39 influenza pandemic were caused by secondary bacterial pneumonia.
40 therapeutic interventions for patients with bacterial pneumonia.
41 efenses and inflammatory injury during acute bacterial pneumonia.
42 influx in human disease during Gram-negative bacterial pneumonia.
43 e to influenza sensitizes hosts to secondary bacterial pneumonia.
44 munity-acquired and nosocomial gram-negative bacterial pneumonia.
45 ormly exhibited severe changes indicative of bacterial pneumonia.
46 s could provide a novel mechanism to prevent bacterial pneumonia.
47 has been linked to an increased incidence of bacterial pneumonia.
48 ated with their ability to support secondary bacterial pneumonia.
49 ions for future efforts to prevent and treat bacterial pneumonia.
50 on; 9 patients recovered fully and 1 died of bacterial pneumonia.
51 at viruses contribute to the pathogenesis of bacterial pneumonia.
52 d to prevent excess mortality from secondary bacterial pneumonia.
53 nsin and inflammatory elements occurs during bacterial pneumonia.
54 munity-acquired and nosocomial gram-negative-bacterial pneumonia.
55 ght be useful in determining the presence of bacterial pneumonia.
56 deficiency of CD4 lymphocytes predisposes to bacterial pneumonia.
57 anges and tissue injury during-gram negative bacterial pneumonia.
58 ry end point was M. avium complex disease or bacterial pneumonia.
59 .16) were also significantly associated with bacterial pneumonia.
60 re not significantly associated with risk of bacterial pneumonia.
61 travenous TPN) would impair immunity against bacterial pneumonia.
62 ve treatment for patients with gram-negative bacterial pneumonia.
63 itial empiric treatment of hospital-acquired bacterial pneumonia.
64 overexpressed in mammalian lungs infected by bacterial pneumonia.
65 nts, two patient groups with a high risk for bacterial pneumonia.
66 a) is a pathological factor also critical in bacterial pneumonia.
67 the transcriptome to identify signatures of bacterial pneumonia.
68 reventing development of viral and secondary bacterial pneumonia.
69 mensional assessment of the host response to bacterial pneumonia.
70 II study in patients with community-acquired bacterial pneumonia.
71 structure infections and community-acquired bacterial pneumonia.
72 may improve the diagnosis and management of bacterial pneumonia.
73 structure infections and community-acquired bacterial pneumonia.
74 d regeneration of alveolar epithelium during bacterial pneumonia.
75 ry pneumonia or be associated with secondary bacterial pneumonia.
76 neurologic sequelae consequent to nosocomial bacterial pneumonia.
77 and atelectasis, which are commonly seen in bacterial pneumonia.
78 d in alveolar epithelial regeneration during bacterial pneumonia.
79 n is critical in determining the severity of bacterial pneumonia.
80 hat promotes alveolar regeneration following bacterial pneumonia.
81 mmon pathogens that cause community-acquired bacterial pneumonia.
82 reptococcus pneumoniae, a causative agent of bacterial pneumonia.
83 infections, dehydration, heart failure, and bacterial pneumonia.
84 of C-reactive protein (CRP) for identifying bacterial pneumonia.
85 tion, and incidence of ventilator-associated bacterial pneumonia.
86 tical illness, is clinically associated with bacterial pneumonia.
87 3 trials for treatment of community-acquired bacterial pneumonia.
88 s increased rates of bacteremia with certain bacterial pneumonias.
89 liminating and preventing the development of bacterial pneumonias.
90 V infections with other viral, atypical, and bacterial pneumonias.
91 from SP-B may be useful in the treatment of bacterial pneumonias.
92 women, 82540 [44.6%]; most common diagnosis bacterial pneumonia, 32634 [17.7%]), a total of 34578 pa
93 Among 119 HIV-negative cases with confirmed bacterial pneumonia, 77% had CRP >/=40 mg/L compared wit
94 mL ATP), viral infection (70 ng/mL ATP), and bacterial pneumonia (92 ng/mL ATP) were significantly di
95 greater in children with PCP than those with bacterial pneumonias (96 of 105 hospital days vs 15 of 9
96 sively studied in the arena of Gram-negative bacterial pneumonia, a role for T cells remains unknown.
100 ilure/rejection (aHR, 2.5; 95% CI, 1.5-4.1), bacterial pneumonia (aHR, 2.8; 95% CI, 2.0-3.9), viral p
101 tion for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin st
102 tional clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin st
103 orithm that screens for predictors of likely bacterial pneumonia and adverse pneumonia outcome could
104 is a need for better prediction of unlikely bacterial pneumonia and adverse pneumonia outcome in ord
105 was used to identify predictors of unlikely bacterial pneumonia and adverse pneumonia outcome, which
107 luenza A viruses can contribute to secondary bacterial pneumonia and deletions in the NA stalk may mo
108 were classified as having likely or unlikely bacterial pneumonia and followed for outcome assessment.
109 ys an essential role in host defense against bacterial pneumonia and in leukocyte antibacterial effec
110 CRP was positively associated with confirmed bacterial pneumonia and negatively associated with RSV p
112 the human nasopharynx and a leading cause of bacterial pneumonia and otitis media, among other invasi
113 disease, the incidence of acute bronchitis, bacterial pneumonia and P. carinii pneumonia is high des
114 stages of HIV infection, incidence rates of bacterial pneumonia and P. carinii pneumonia rise contin
115 y distress such as malaria or distinguishing bacterial pneumonia and pneumonia from others causes, su
116 virus neuraminidase contributes to secondary bacterial pneumonia and subsequent excess mortality.
118 work in the indications of hospital-acquired bacterial pneumonia and ventilator-associated bacterial
119 n ration (p < .001), and those patients with bacterial pneumonia and viral pneumonitis had decreased
120 re, and oxygen saturation than children with bacterial pneumonia and were less likely to have a focal
122 All 68 cases had histological evidence of bacterial pneumonia, and 94% showed abundant bacteria on
123 influenza B virus, characterize concomitant bacterial pneumonia, and describe the spectrum of cardio
124 D4 counts < 200 cells/mm3, acute bronchitis, bacterial pneumonia, and P. carinii pneumonia occurred a
125 Staphylococcus aureus is a leading cause of bacterial pneumonia, and we have shown previously that t
130 One hundred fifteen (76%) responders chose bacterial pneumonia as a condition consistent with infil
131 sis, prophylaxis, and treatment of secondary bacterial pneumonia, as well as stockpiling of antibioti
132 possible contributor to the common secondary bacterial pneumonia associated with pandemic and seasona
134 eumocystis carinii pneumonia (PCP), but also bacterial pneumonia (BP), result in reductions in lung f
135 negatively regulates CXCL1/KC levels during bacterial pneumonia but that the role of GRK5 in the cli
136 neration ketolide, was effective in treating bacterial pneumonia, but it was not approved by the U.S.
137 neration ketolide, was effective in treating bacterial pneumonia, but it was not approved by the U.S.
138 lar vesicles (EV) can reduce the severity of bacterial pneumonia, but little is known about the mecha
139 orted that leptin plays a protective role in bacterial pneumonia, but the mechanisms by which leptin
140 t M-CSF is critical to host defenses against bacterial pneumonia by mediating survival and antimicrob
141 lpha-Toc enhances resistance of aged mice to bacterial pneumonia by modulating the innate immune resp
142 nistration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and
143 rials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacter
147 infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) were based on nonstandardized
150 infection and to test whether signatures of bacterial pneumonia can be identified in the alveolar ma
153 emic likely resulted directly from secondary bacterial pneumonia caused by common upper respiratory-t
154 learly and consistently implicated secondary bacterial pneumonia caused by common upper respiratory-t
156 o determine the role of TNF in gram-negative bacterial pneumonia, CBA/J mice were challenged with 10(
158 which was defined as a composite endpoint of bacterial pneumonia (confirmed by the endpoint review co
159 sion rates for all types of ACSCs, including bacterial pneumonia, congestive heart failure, dehydrati
161 ion of new mechanisms in the pathogenesis of bacterial pneumonia could lead to future therapeutic tar
163 n of 16 children with PCP and six of 21 with bacterial pneumonia died (relative risk 2.19 [95% CI 1.0
165 concentration (p=0.004), and more cumulative bacterial pneumonia episodes (12 month lag only; p trend
166 these factors, CD4/CD8 ratio and cumulative bacterial pneumonia episodes remained significant (p tre
167 n-bacterial pneumonia; whereas children with bacterial pneumonia, exhibited increased severity (OR 8.
171 ed as a diagnostic marker in differentiating bacterial pneumonia from other respiratory conditions su
172 athways, including facilitation of secondary bacterial pneumonia from pathogens such as Streptococcus
174 hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are im
175 ve guidance for studies of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bac
176 n hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positi
177 f hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resis
182 eased risk of both common infections such as bacterial pneumonia (hazard ratio [HR], 1.50 [95% confid
183 e assessed incidence of and risk factors for bacterial pneumonia in 1,898 human immunodeficiency viru
185 lear phagocyte-mediated host defenses during bacterial pneumonia in a murine model of infection.
189 ive predictive value of greater than 90% for bacterial pneumonia in both the retrospective (n = 851)
191 lia has a high negative predictive value for bacterial pneumonia in critically ill patients with susp
192 absence of alveolar neutrophilia can exclude bacterial pneumonia in critically ill patients with susp
193 CN2 levels were tremendously elevated during bacterial pneumonia in humans, and high LCN2 levels were
196 ILC3s) are critical for lung defense against bacterial pneumonia in the neonatal period, but the sign
198 f alveolar neutrophilia for the diagnosis of bacterial pneumonia in three cohorts of mechanically ven
199 o determine its role in host defense against bacterial pneumonia in vivo and in alveolar macrophage (
200 Despite the widespread use of antibiotics, bacterial pneumonias in donors strongly predispose to th
201 nees/military recruits were due to secondary bacterial pneumonias; in contrast, most deaths among Rot
202 Other mediators of innate immunity against bacterial pneumonia include transepithelial dendritic ce
205 ce rates (IRs) per 100 person-years were 123 bacterial pneumonia (IR, 2.15; 95% confidence interval [
223 plasma from patients with ARDS secondary to bacterial pneumonia is toxic to SPAEC, and a small but s
228 reptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and sepsis in children
229 y the role of specific T cell populations in bacterial pneumonia, mice deleted of their TCR beta- and
230 oniae (the pneumococcus) is a major cause of bacterial pneumonia, middle ear infection (otitis media)
231 dase (MPO) colocalized with SP-D in a murine bacterial pneumonia model of acute inflammation, suggest
232 sublethal hyperoxia increases Gram-negative bacterial pneumonia mortality and has a significant adve
233 ltiple pathogens, e.g., the life-threatening bacterial pneumonia observed in patients infected with i
236 associated with significantly lower odds of bacterial pneumonia (odds ratio 0.39, 95% confidence int
238 ptococcus pneumoniae is a causative agent of bacterial pneumonia, otitis media, meningitis, and bacte
239 buted to influenza virus is due to secondary bacterial pneumonia, particularly from Streptococcus pne
240 total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [P
241 a 1:1 ratio) adults with community-acquired bacterial pneumonia (Pneumonia Severity Index risk class
242 specificity of elevated CRP for "confirmed" bacterial pneumonia (positive blood culture or positive
244 ndotoxin after successful treatment of donor bacterial pneumonia promotes PGD through ischemia/reperf
245 five in the placebo group (1.9 percent) had bacterial pneumonia (relative risk in the azithromycin g
251 e transgenic expression of MIP-1alpha during bacterial pneumonia resulted in enhanced expression of g
252 been a dramatic decline in the incidence of bacterial pneumonia resulting from the use of combinatio
253 mens was associated with a decreased risk of bacterial pneumonia (risk ratio [RR] 0.55, 95% CI 0.31 t
254 a well-established murine model of secondary bacterial pneumonia (SBP) following influenza, we strati
255 nt of 37.1 mg/L best discriminated confirmed bacterial pneumonia (sensitivity 77%) from RSV pneumonia
256 Streptococcus (GBS) is the leading cause of bacterial pneumonia, sepsis, and meningitis among neonat
258 Legionella pneumophila, a causative agent of bacterial pneumonia, survives inside phagocytic cells by
260 infection predisposes patients to secondary bacterial pneumonia that contributes significantly to mo
261 on model of the intrahost immune response to bacterial pneumonia that is capable of capturing diverse
262 icient mice display impaired host defense in bacterial pneumonia that may be due to a defect in alveo
263 ased morbidity and mortality associated with bacterial pneumonias that are acquired following influen
264 al pneumopathogens and can lead to secondary bacterial pneumonias that greatly contribute to respirat
265 o a significant number of cases of secondary bacterial pneumonia, this highly pathogenic strain of in
266 cases are viral, it is important to identify bacterial pneumonia to provide appropriate therapy.
268 ns were much the same as in controls: 18 had bacterial pneumonia, two tuberculosis, five cryptococcal
269 or of inflammation in a mouse model of acute bacterial pneumonia using the opportunistic bacterial pa
271 flox)) to littermate controls during direct (bacterial pneumonia, ventilator-induced ALI, bleomycin-i
272 une response that favored the development of bacterial pneumonia via the inhibition of bacterial phag
273 ia, infection with Cryptococcus or Nocardia, bacterial pneumonia, viral pneumonia, and Kaposi's sarco
275 aspirates were collected from children with bacterial pneumonia, viral pneumonitis, ARDS, postcardio
281 ip of combination antiretroviral therapy and bacterial pneumonia, we assessed incidence of and risk f
282 mine the role of MyD88 in innate immunity to bacterial pneumonia, we exposed MyD88-deficient and wild
283 the lung in response to LPS or Gram-negative bacterial pneumonia, we hypothesized that IL-17RA signal
284 new approaches to enhance innate immunity to bacterial pneumonia, we investigated the natural experim
287 filtrates on chest radiographs suggestive of bacterial pneumonia were common among those needing hosp
290 similar severity to children with other non-bacterial pneumonia; whereas children with bacterial pne
292 evels enable the practitioner to distinguish bacterial pneumonia, which requires antibiotic therapy,
293 c influenza predispose patients to secondary bacterial pneumonias, which are a major cause of deaths
295 ion was characterized by viral and secondary bacterial pneumonia with 67% having positive RT-PCR in s
297 ic mechanisms in a lethal model of secondary bacterial pneumonia with an S. pneumoniae strain that is
299 ned as documented bacteremia or any presumed bacterial pneumonia with or without positive respiratory
300 rom both cell types identified patients with bacterial pneumonia with test characteristics similar to